TP53 and lung cancer: Moreover, a recent study analyzing lung cancer patients treated with PD-L1 blockade reported that patients harboring both KRAS and TP53 mutations were resistant to immunotherapy through a mechanism that was independent of PD-L1 expression levels (Skoulidis et al., 2018).